论文部分内容阅读
目的:观察柔肝灵颗粒联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法:将确诊为慢性乙型肝炎肝纤维化的80例患者按随机数字表法分为两组,治疗组50例采用柔肝灵颗粒联合恩替卡韦分散片治疗,对照组30例单用恩替卡韦分散片治疗。两组疗程均为32周。结果:总有效率治疗组为94.0%,对照组为73.3%,组间比较,差异有统计学意义(P<0.05)。两组肝纤维化血清学指标及临床症状、体征改善情况比较,差异均有统计学意义(P<0.05)。结论:柔肝灵颗粒联合恩替卡韦治疗慢性乙型肝炎肝纤维化疗效显著,值得临床推广应用。
Objective: To observe the clinical efficacy of Rouganling granule combined with entecavir in treating chronic hepatitis B liver fibrosis. Methods: Eighty patients diagnosed with chronic hepatitis B liver fibrosis were divided into two groups according to the random number table. The treatment group (50 cases) was treated with Rouganling granules combined with entecavir dispersible tablets. The control group, 30 cases were treated with entecavir dispersible tablets treatment. The two groups were treated for 32 weeks. Results: The total effective rate was 94.0% in the treatment group and 73.3% in the control group. There was significant difference between the two groups (P <0.05). Serum indicators of liver fibrosis and clinical symptoms and signs of two groups improved, the differences were statistically significant (P <0.05). Conclusion: Rouganling granule combined with entecavir treatment of chronic hepatitis B liver fibrosis significant effect, worthy of clinical application.